Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 38

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 38
---
 Officer and Executive Director |
| Professor Sir John Bell       |     |  72 |     | Chairman of the Board of Directors             |
| Roy S. Herbst, M.D., Ph.D.    |     |  62 |     | Director                                       |
| Siddharth Kaul                |     |  64 |     | Director                                       |
| Ranjeev Krishana              |     |  51 |     | Director                                       |
| William Pao, M.D., Ph.D.      |     |  57 |     | Director                                       |
| Robert Perez                  |     |  60 |     | Director                                       |
| Kristine Peterson             |     |  65 |     | Director                                       |
| Professor Sir Peter Ratcliffe |     |  70 |     | Director                                       |

Biographical information for those directors who are not standing for re-election at the AGM and who will remain seated following the AGM, including each such individual’s principal occupation, business experience and education, and an explanation of the qualifications, skills and experiences that we believe are relevant to such individual’s service on our board of directors, are set forth below. The biographies of Dr. Herbst, Mr. Krishana and Professor Sir Peter Ratcliffe are set forth above in resolutions 1, 2 and 3, respectively. Class II Directors Continuing in Office Until the 2026 Annual General Meeting Siddharth Kaul has served on our board of directors since June 2022. Mr. Kaul is a seasoned finance professional with deep expertise within the life sciences industry. He retired as Group Treasurer and Head of Business Planning and Analysis at Novartis in 2021 after a 17-year career at the company, where his previous roles included serving as Novartis' Chief Financial Officer, Pharma Europe and Chief Financial Officer, Pharma U.S. Mr. Kaul led the Novartis strategic review and spin-off of Alcon, Novartis' eye care business. Prior to joining Novartis, Mr. Kaul spent two decades at Procter & Gamble, where he worked in a number of finance leadership roles across financial planning and analysis, strategic planning, and accounting and auditing in the United States and Japan. Mr. Kaul holds a B.S. in Business Administration from West Virginia University and an M.B.A. from Indiana University Bloomington. We believe that Mr. Kaul's extensive experience in finance qualifies him to serve on our board of directors. William Pao, M